Alan M. Miller, MD, PhD

One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System, discusses immunotherapy for cancer treatment.